Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Gallagher, David A.
and
Schrag, Anette
2012.
Psychosis, apathy, depression and anxiety in Parkinson's disease.
Neurobiology of Disease,
Vol. 46,
Issue. 3,
p.
581.
Connolly, Barbara S
and
Fox, Susan H
2012.
Drug treatments for the neuropsychiatric complications of Parkinson’s disease.
Expert Review of Neurotherapeutics,
Vol. 12,
Issue. 12,
p.
1439.
QUELHAS, ROSA
2013.
Psychiatric Care in Parkinson’s Disease.
Journal of Psychiatric Practice,
Vol. 19,
Issue. 2,
p.
118.
Carvalho, Miguel M
Campos, Filipa L
Coimbra, Bárbara
Pêgo, José M
Rodrigues, Carla
Lima, Rui
Rodrigues, Ana J
Sousa, Nuno
and
Salgado, António J
2013.
Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits.
Molecular Neurodegeneration,
Vol. 8,
Issue. 1,
Biemiller, Rachel
and
Richard, Irene Hegeman
2014.
Managing Depression in Parkinson’s Patients: Risk Factors and Clinical Pearls.
Neurodegenerative Disease Management,
Vol. 4,
Issue. 4,
p.
329.
Connolly, Barbara
and
Fox, Susan H.
2014.
Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease.
Neurotherapeutics,
Vol. 11,
Issue. 1,
p.
78.
Dyduch, Agnieszka
and
Załuska, Maria
2015.
Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review.
Psychogeriatrics,
Vol. 15,
Issue. 2,
p.
147.
Kapfhammer, H.-P.
2015.
Psychiatrie, Psychosomatik, Psychotherapie.
p.
1.
Huot, Philippe
Fox, Susan H.
and
Brotchie, Jonathan M.
2015.
Monoamine Reuptake Inhibitors in Parkinson’s Disease.
Parkinson's Disease,
Vol. 2015,
Issue. ,
p.
1.
Cooney, Jeffrey W.
and
Stacy, Mark
2016.
Neuropsychiatric Issues in Parkinson’s Disease.
Current Neurology and Neuroscience Reports,
Vol. 16,
Issue. 5,
Kapfhammer, Hans-Peter
2017.
Psychiatrie, Psychosomatik, Psychotherapie.
p.
2693.
Zhao, Mengnan
and
Yang, Christopher C
2018.
Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.
Journal of Medical Internet Research,
Vol. 20,
Issue. 10,
p.
e271.
Rakofsky, Jeffrey
and
Rapaport, Mark
2018.
Mood Disorders.
CONTINUUM: Lifelong Learning in Neurology,
Vol. 24,
Issue. 3,
p.
804.
Ryan, Melody
Eatmon, Courtney V.
and
Slevin, John T.
2019.
Drug treatment strategies for depression in Parkinson disease.
Expert Opinion on Pharmacotherapy,
Vol. 20,
Issue. 11,
p.
1351.
Butala, Ankur
Shepard, Melissa
and
Pontone, Greg
2019.
Psychopharmacology of Neurologic Disease.
Vol. 165,
Issue. ,
p.
83.
Uhl, George R.
2019.
Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.
Annals of Clinical and Translational Neurology,
Vol. 6,
Issue. 2,
p.
406.
Wang, Yingtan
Lu, Zhe
and
Xun, Guanglei
2021.
Pathological gambling in a patient on piribedil.
Medicine,
Vol. 100,
Issue. 6,
p.
e24568.
Müller, Thomas
2021.
Experimental Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of the Evidence.
Journal of Experimental Pharmacology,
Vol. Volume 13,
Issue. ,
p.
397.
Dhingra, Amitha
Janjua, A. Umair
Hack, Laura
Waserstein, Gabriella
Palanci, Justin
and
Hermida, Adriana P.
2021.
Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting.
Journal of Geriatric Psychiatry and Neurology,
Vol. 34,
Issue. 3,
p.
181.
Lee, Wing‐King
Au Yeung, Kwok‐Leung
Lam, Ho‐Bun
Wong, Chi‐Keung
Wong, Ting‐Chi
Fu, Chi‐Kin
Sham, Shiu‐Kow
Au, Ming‐Kai
Lam, Tat‐Chung
and
Ki‐Yan Mak, Daniel
2021.
Consensus statements on the clinical understanding and use of bupropion in Hong Kong.
CNS Neuroscience & Therapeutics,
Vol. 27,
Issue. S1,
p.
20.